Artificial Intelligence In Drug Discovery Market Size 2025-2029
The artificial intelligence in drug discovery market size is forecast to increase by USD 4.32 billion at a CAGR of 25.7% between 2024 and 2029.
- Artificial Intelligence (AI) is revolutionizing the drug discovery market, offering significant potential for accelerating the development of new therapies. Key growth factors include the availability of funding and strategic partnerships between industry players and tech companies. However, regulatory hurdles pose a challenge, as AI applications in drug discovery must meet stringent regulatory requirements.
- Additionally, the use of AI in drug discovery is trending, with its ability to process vast amounts of data and identify potential drug candidates more efficiently than traditional methods. This market analysis report provides an in-depth examination of these factors and their impact on the drug discovery market's growth trajectory. AI's potential to transform the pharmaceutical industry is undeniable, and this report offers valuable insights into the opportunities and challenges associated with its adoption. AI-powered safety monitoring systems ensure that drugs meet professional certifications and regulatory requirements, while medical devices and medical diagnostics benefit from AI for biopharma in target identification and AI certification for professional standards.
What will be the Size of the Market During the Forecast Period?
- Artificial Intelligence (AI) is revolutionizing the drug discovery market by offering innovative solutions to optimize various stages of the drug development lifecycle. From drug structure optimization to clinical trial optimization, AI is transforming the way new drugs are discovered and developed. One of the significant applications of AI in drug discovery is personalized medicine, where it aids in disease prediction and precision medicine. By analyzing gene data and variant data, AI algorithms can identify potential drug targets and predict their efficacy for specific patient populations. AI also plays a crucial role in drug delivery, drug resistance, and drug safety. It assists in optimizing drug delivery systems, identifying potential drug resistance mechanisms, and monitoring drug safety during clinical development.
- Moreover, AI is facilitating biomarker discovery, drug disease association, hit compounds identification, and drug repurposing. It analyzes vast amounts of data from biotechnology and healthcare innovation to identify new drug targets and associations between diseases and drugs. The drug discovery platform is also evolving with AI, enabling faster and more efficient drug development.
-
Additionally, pharmaceutical innovation continues to thrive with AI, as it streamlines the drug development process, enhances drug design, and supports regulatory compliance. The integration of AI in drug manufacturing and clinical development further accelerates the pace of innovation in the healthcare sector. In conclusion, AI is a game-changer in the drug discovery market, offering numerous benefits from drug structure optimization to regulatory compliance. Its applications in personalized medicine, drug delivery, drug resistance, drug safety, biomarker discovery, and drug development lifecycle are transforming the pharmaceutical industry and driving healthcare innovation.
How is this market segmented and which is the largest segment?
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD billion" for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.
- Deployment
- Cloud-based
- On-premises
- Therapeutic Area
- Oncology
- Infectious diseases
- Neurology
- Metabolic diseases
- Others
- Geography
- North America
- Canada
- US
- Europe
- Germany
- UK
- France
- APAC
- China
- India
- South Korea
- South America
- Middle East and Africa
- North America
By Deployment Insights
- The cloud-based segment is estimated to witness significant growth during the forecast period.
Artificial Intelligence (AI) plays a crucial role in the drug discovery market, particularly through the application of advanced cloud-based solutions. These technologies offer advantages such as scalability, accessibility, and computational power, enabling companies to accelerate the drug discovery process more effectively. For instance, XtalPi, a global technology company, utilizes AI, quantum physics, and robotics to innovate in life sciences, chemistry, and new materials. By partnering with Amazon Web Services (AWS), XtalPi supports over 150 companies, including 16 of the world's leading pharmaceutical firms, in expediting drug discovery and development. This collaboration underscores the significance of AI in driving innovation and efficiency within the drug discovery industry.
Get a glance at the market report of share of various segments Request Free Sample
The cloud-based segment was valued at USD 436.40 million in 2019 and showed a gradual increase during the forecast period.
Regional Analysis
- North America is estimated to contribute 36% to the growth of the global market during the forecast period.
Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
For more insights on the market share of various regions Request Free Sample
The United States, a key player in the global artificial intelligence (AI) market for drug discovery, is driven by substantial investments and innovative initiatives. Advanced technological capabilities, a robust infrastructure, and strong venture capital support fuel the growth and development of AI-driven drug discovery in North America. For instance, Xaira Therapeutics, a US-based company, was launched in April 2024 with a mission to transform drug discovery and development using emerging AI technologies. Backed by over USD1 billion in funding from investors like ARCH Venture Partners and Foresite Labs, Xaira integrates advanced machine learning research, extensive data generation, and robust therapeutic product development. This integration aims to streamline the drug discovery process and bring innovative treatments to market more efficiently.
Market Dynamics
Our researchers analyzed the data with 2024 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
What are the key market drivers leading to the rise in the adoption of Artificial Intelligence In Drug Discovery Market?
Availability of funding is the key driver of the market.
- Artificial Intelligence (AI) is revolutionizing the drug development landscape, particularly in the area of drug discovery for chronic diseases. AI technologies, such as machine learning and computational tools, are being employed to identify disease events and potential drug targets, streamlining the discovery process and reducing time-consuming experiments. Protein pockets and receptor targets are being analyzed with greater accuracy, leading to the design of more effective therapeutic drugs.
- Additionally, AI-based drug discovery is also facilitating collaborations between biopharma companies and academic institutions, enabling the sharing of data and expertise to uncover novel drug targets. Cloud-based services are making these advanced technologies more accessible, reducing costs for businesses and accelerating preclinical studies. Safety monitoring is another area where AI is making a significant impact, enabling the identification of potential side effects and adverse reactions earlier in the development process. Overall, the availability of substantial investments in AI technologies is driving innovation and accelerating the development of biopharmaceutical products, ultimately benefiting patients and the healthcare industry.
What are the market trends shaping the Artificial Intelligence In Drug Discovery Market?
Strategic partnerships are the upcoming trends in the market.
- The Artificial Intelligence (AI) market in drug discovery is experiencing a notable trend towards strategic collaborations among biopharma companies and technology providers. These partnerships are crucial for harnessing advanced AI technologies to expedite and enhance drug discovery processes, tackle intricate challenges, and boost efficiency. For instance, in September 2024, Insilico Medicine, a US-based clinical-stage biotech firm specializing in generative AI, announced a collaboration with Inimmune. This alliance utilizes Insilico's proprietary AI technology, Chemistry42, to accelerate the discovery and development of novel immunotherapeutics. During the initial phase, Inimmune leveraged Chemistry42's capabilities to address specific challenges in their drug discovery efforts.
- Additionally, AI technologies, such as machine learning and cloud-based services, are revolutionizing drug discovery by providing computational tools for predicting protein pockets, identifying drug targets, and designing drug structures. By streamlining preclinical studies and safety monitoring, AI-based drug discovery is reducing the time-consuming and expensive nature of traditional methods. This market dynamic is expected to significantly impact the biopharmaceutical industry, leading to the development of innovative therapeutics for chronic diseases and disease events.
What challenges does Artificial Intelligence In Drug Discovery Market face during the growth?
Regulatory hurdles are key challenges affecting the market growth.
- Artificial Intelligence (AI) plays a pivotal role in revolutionizing drug discovery, particularly in the identification of novel therapeutic drugs for chronic diseases. AI technologies, including machine learning and deep learning, are employed to analyze disease events and gene sequences, enabling the discovery of new protein pockets and drug targets. These computational tools significantly reduce the time-consuming and expensive process of drug structure design and preclinical studies. AI-based drug discovery has gained traction among biopharma companies, leading to increased investment in this area.
- However, regulatory hurdles pose a challenge to the widespread adoption of AI in drug discovery. The US Food and Drug Administration (FDA) has issued guidelines to ensure AI-driven methodologies meet safety, effectiveness, and quality standards. AI applications in drug discovery include safety monitoring, clinical development, and collaborations between biotechnology and medical device companies. Ligand molecule discovery, receptor targets, and therapeutic drugs are some of the areas where AI technologies have shown promise. Despite these advancements, the integration of AI in drug discovery requires careful consideration to navigate regulatory complexities and maintain the highest standards of patient safety and efficacy.
Exclusive Customer Landscape
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Key Companies & Market Insights
Companies are implementing various strategies, such as strategic alliances, market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Atomwise Inc. - This company pioneers artificial intelligence (AI) innovations in the drug discovery sector, leveraging its advanced AtomNet technology. AtomNet represents a groundbreaking development in drug discovery algorithms, incorporating a deep convolutional neural network as its core. By harnessing the power of AI, this solution streamlines the drug discovery process, enhancing efficiency and accuracy in identifying potential therapeutic candidates.
The market research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
- Atomwise Inc.
- BenevolentAI
- C4X Discovery Holdings PLC
- Deep Genomics Inc.
- Enamine Ltd
- Evotec SE
- GNS Healthcare Inc.
- Insilico Medicine
- PathAI Inc.
- Phenomic AI Inc.
- Recursion Pharmaceuticals
- Roivant Sciences Ltd.
- Schrodinger Inc.
- Verge Analytics Inc.
- Zoetis Inc.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Research Analyst Overview
Artificial Intelligence (AI) is transforming various industries, and drug discovery is no exception. The application of AI technologies in drug development is revolutionizing the way therapeutic drugs are discovered and designed, particularly for chronic diseases. Drug discovery is a complex and time-consuming process, often involving the identification of disease events and their underlying causes. Traditional methods relied on labor-intensive experiments, which could take years to yield results. However, the advent of AI technologies is streamlining this process by enabling the analysis of vast amounts of data related to genes, proteins, and disease mechanisms.
Additionally, AI technologies, including machine learning and deep learning, are being used to identify novel drug targets and design drug structures. These computational tools can analyze large datasets to identify patterns and correlations that may not be apparent through traditional methods. For instance, AI algorithms can analyze the structure of proteins and their interaction with ligand molecules to identify potential therapeutic targets. Moreover, AI technologies are being used for safety monitoring during clinical development. These systems can analyze patient data and identify potential safety concerns, enabling early intervention and reducing the risk of adverse events. Collaborations between biopharma companies and AI technology providers are on the rise, as the potential benefits of AI-based drug discovery become increasingly apparent.
Moreover, these collaborations enable biopharma companies to leverage the power of AI technologies without having to invest in developing them in-house. Cloud-based services are also playing a significant role in the adoption of AI technologies in drug discovery. These services provide access to powerful computational tools and vast amounts of data, enabling researchers to analyze and interpret data more efficiently. Despite the potential benefits, the high cost of developing and testing new drugs remains a significant challenge. AI technologies are expected to help reduce the time and cost of drug development by identifying potential drug targets more accurately and designing drugs more efficiently.
In conclusion, AI technologies are transforming drug discovery efforts, enabling the identification of novel drug targets, designing drug structures, and improving safety monitoring during clinical development. The use of AI technologies in drug discovery is expected to reduce the time and cost of developing new drugs, making biopharmaceutical products more accessible to patients. The future of drug discovery is exciting, and AI technologies are at the forefront of this revolution.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
207 |
|
Base year |
2024 |
|
Historic period |
2019-2023 |
|
Forecast period |
2025-2029 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 25.7% |
|
Market growth 2025-2029 |
USD 4.32 billion |
|
Market structure |
Fragmented |
|
YoY growth 2024-2025(%) |
24.3 |
|
Key countries |
US, China, UK, Germany, Canada, Australia, UAE, India, France, and South Korea |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
What are the Key Data Covered in this Market Research and Growth Report?
- CAGR of the market during the forecast period
- Detailed information on factors that will drive the market growth and forecasting between 2025 and 2029
- Precise estimation of the size of the market and its contribution of the market in focus to the parent market
- Accurate predictions about upcoming market growth and trends and changes in consumer behaviour
- Growth of the market across North America, Europe, APAC, South America, and Middle East and Africa
- Thorough analysis of the market's competitive landscape and detailed information about companies
- Comprehensive analysis of factors that will challenge the growth of market companies
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch